Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma. The study aims to evaluate the safety and efficacy of odronextamab, an experimental bispecific antibody, combined with lenalidomide, compared to the current standard treatment of rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma. This research is significant as it explores a potentially more effective treatment option for these lymphoma subtypes.
The intervention being tested is odronextamab, administered via intravenous infusion, in combination with lenalidomide, taken orally. This combination is being compared to rituximab, administered either intravenously or subcutaneously, with lenalidomide.
The study is designed as an open-label, randomized trial with a parallel assignment. It includes two parts: a safety run-in phase to determine the appropriate dose of odronextamab, followed by a randomized phase to compare the efficacy of the two treatment combinations. There is no masking involved, and the primary purpose is treatment.
The study began on November 20, 2023, with an estimated primary completion date in 2025. The last update was submitted on August 20, 2025. These dates are crucial as they indicate the timeline for potential data availability and subsequent analysis.
This clinical trial update could influence Regeneron’s stock performance and investor sentiment positively, especially if the results demonstrate superior efficacy of odronextamab over the current standard of care. The outcome may also impact the competitive landscape in the treatment of non-Hodgkin’s lymphoma, where advancements are closely watched by industry stakeholders.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.